Dr. Reddy’s Laboratories Announces Launch of Oral Semaglutide Biosimilar ‘Obeda®’ (tablets) in India

Meida News Ludhiana, May 20

A Global pharmaceutical Leader Dr. Reddy’s Laboratories Ltd., today announced the launch of its oral semaglutide biosimilar, indicated for type 2 diabetes mellitus. Dr. Reddy’s oral semaglutide is available in tablet form under the brand name Obeda® in India. This launch follows Dr. Reddy’s recent generic Semaglutide injection launches in India and Canada, further establishing the company’s position as a full-stack player in GLP-1 therapies.

M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s, said “The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care. We recognize that every patient’s journey with diabetes is different, and treat-ment choices must reflect that diversity. With this launch, we are broadening our GLP-1 portfolio to offer patients more choice and flexibility. As the product is developed and formulated in-house, we are committed to reliable supply and con-sistent quality for patients in India. As we continue to build a comprehensive GLP-1 portfolio, we are focused on delivering innovation, high-quality, and affordabili-ty, translating into meaning-ful treatment options and better long-term outcomes for people living with chron-ic metabolic diseases in India and beyond.”

As per the ICMR-INDIAB study, India represents one of the world’s largest dia-betes burdens with over 101 million adults living with the condition and a prevalence of 11.4%. Alarmingly, nearly 136 million individuals are prediabetic, and close to 40% of adults have abdomi-nal obesity, placing them at high risk of progression[1]. Despite multiple treatment options, uncontrolled type 2 diabetes remains a signifi-cant challenge.